1 week Ago By Defense World Staff
Prudential Financial Inc. lessened its position in Metagenomi, Inc. ( NASDAQ:MGX – Free Report ) by 37.
0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 13,725 shares of the company’s stock after selling 8,075 shares during the quarter. Prudential Financial Inc.
’s holdings in Metagenomi were worth $50,000 as of its most recent SEC filing. A number of other institutional investors have also recently made changes to their positions in MGX. Rhumbline Advisers lifted its holdings in Metagenomi by 123.
3% in the 4th quarter. Rhumbline Advisers now owns 11,998 shares of the company’s stock valued at $43,000 after purchasing an additional 6,626 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Metagenomi in the fourth quarter valued at about $43,000.
BNP Paribas Financial Markets lifted its stake in shares of Metagenomi by 130.9% in the third quarter. BNP Paribas Financial Markets now owns 12,799 shares of the company’s stock worth $28,000 after buying an additional 7,256 shares in the last quarter.
Corebridge Financial Inc. boosted its position in Metagenomi by 303.1% during the fourth quarter.
Corebridge Financial Inc. now owns 13,602 shares of the company’s stock worth $49,000 after acquiring an additional 10,228 shares during the last quarter. Finally, Virtu Financial LLC purchased a new stake in Metagenomi during the 3rd quarter valued at about $33,000.
Wall Street Analysts Forecast Growth MGX has been the topic of a number of research reports. Wells Fargo & Company decreased their target price on shares of Metagenomi from $25.00 to $20.
00 and set an “overweight” rating on the stock in a research note on Tuesday, March 18th. HC Wainwright reduced their price objective on Metagenomi from $14.00 to $7.
00 and set a “buy” rating on the stock in a research report on Thursday, April 3rd. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, Metagenomi presently has an average rating of “Moderate Buy” and a consensus price target of $13.
00. Metagenomi Price Performance Shares of NASDAQ MGX opened at $1.48 on Friday.
The company has a market capitalization of $55.33 million, a P/E ratio of -0.56 and a beta of -0.
27. The company has a 50 day simple moving average of $1.92 and a 200-day simple moving average of $2.
34. Metagenomi, Inc. has a 1 year low of $1.
23 and a 1 year high of $9.67. Metagenomi ( NASDAQ:MGX – Get Free Report ) last posted its earnings results on Monday, March 17th.
The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.
01). Metagenomi had a negative return on equity of 43.23% and a negative net margin of 134.
27%. The business had revenue of $9.61 million for the quarter, compared to analyst estimates of $13.
18 million. During the same period last year, the business earned ($20.05) EPS.
As a group, research analysts expect that Metagenomi, Inc. will post -2.46 EPS for the current year.
Metagenomi Company Profile ( Free Report ) Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. Recommended Stories Five stocks we like better than Metagenomi Trading Halts Explained JPMorgan is a Buy, if You Can Handle The Volatility REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today United States Steel’s Crash: An Unmissable Buying Opportunity P/E Ratio Calculation: How to Assess Stocks Rocket Lab Stock: Weathering the Storm, Time for a Comeback? Receive News & Ratings for Metagenomi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metagenomi and related companies with MarketBeat.
com's FREE daily email newsletter ..
